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doi:10.1016/j.jtcvs.2003.11.056180 The Journal of Thoracic and CardioObjective: This study tested the hypothesis that cardioplegic solution supplemented
with a nitric oxide donor agent attenuates postischemic cardiomyocytic apoptosis by
reduction of mitochondrial complex I up-regulation during global cardiac arrest
under cardiopulmonary bypass.
Methods: Twenty-four anesthetized dogs supported by total vented bypass were
divided evenly into 4 groups (n  6) and subjected to 60 minutes of hypothermic
ischemia followed by 4°C multidose crystalloid cardioplegic solution infusion.
Hearts received either standard crystalloid cardioplegic solution (control), crystal-
loid cardioplegic solution supplemented with 2 mmol/L L-arginine (L-Arg group),
crystalloid cardioplegic solution supplemented with 400 mol/L NG-monomethyl-
L-arginine (L-NMMA group), or crystalloid cardioplegic solution supplemented with
100 mol/L of NO donor compound (3-morpholinosydnonimine; SIN-1 group).
After 60 minutes of cardioplegic arrest, the heart was reperfused for a total of 240
minutes after discontinuation of bypass. The occurrence of cardiomyocytic apopto-
sis was assessed by terminal deoxynucleotidyl transferase–mediated dUTP-biotin
nick end labeling and Western blot analysis of caspase-3.
Results: The occurrence of cardiomyocytic apoptosis was significantly reduced in
SIN-1 and L-Arg groups compared with the control group. Mitochondrial complex
I mRNA was up-regulated in the control group, and its expression was significantly
higher in the L-NMMA group but significantly reduced in the SIN-1 and L-Arg
groups. Western blot analysis of Bcl-2 and cytochrome c, an index of mitochondrial
damage in postischemic myocardium, revealed a similar pattern.
Conclusion: Nitric oxide–supplemented crystalloid cardioplegic solution diminished
postischemic cardiomyocytic apoptosis after global cardiac arrest under cardiopul-
monary bypass, possibly via prevention of mitochondrial complex I up-regulation.
The decreased production of endothelium-derived nitric oxide (NO)has been found to increase myocardial ischemia and reperfusiondamage during global cardiac arrest under cardiopulmonary bypass(CPB).1-3 The physiologic functions of NO include vasodilation,inhibition of platelet aggregation and neutrophil adhesion, and bi-radical quenching of superoxide anions.4 The attenuation of NO
release caused by endothelial damage after reperfusion exacerbates the extent of
postischemic cardiomyocytic injury and may be a critical mechanism in the occur-
rence of cardiomyocytic apoptosis after global cardiac arrest under CPB.
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PIn the development of cardioplegic solutions for use as
cardioprotective strategies, attention has been primarily fo-
cused on protecting cardiomyocytes from necrosis and con-
tractile dysfunction. However, recent studies have demon-
strated that cardiomyocytic apoptosis after global cardiac
arrest under CPB has an important influence on postopera-
tive cardiac function.5 A recent study from our laboratory6
showed that neither intermittent cold crystalloid nor inter-
mittent cold blood cardioplegic solution could protect car-
diomyocytes from apoptosis after global cardiac arrest un-
der CPB. Compared with infusion of continuous tepid blood
cardioplegic solution, the coronary endothelial damage was
also evident in these 2 cardioprotective methods. However,
the protective effect of continuous blood cardioplegic infu-
sion on attenuation of cardiomyocytic apoptosis may come
from preservation of the endothelium, which provides NO
to the underlying cardiomyocytes. Another study from our
laboratory7 revealed that continuous tepid warm blood car-
dioplegic solution could decrease the up-regulation of mi-
tochondrial NADH:ubiquinone oxidoreductase (complex I)
mRNA and reduce mitochondrial free radical production.
However, the possible role of mitochondria and mitochon-
drial complex I in NO-regulated protective effect on the
occurrence of cardiomyocytic apoptosis during global car-
diac arrest under CPB has never been explored.
Cardioplegic solutions could be an ideal vehicle for the
introduction of agents that target the perpetrators of endo-
thelial injury during global cardiac arrest under CPB. Re-
placement of lost (secondary to endothelial damage) endog-
enous NO with exogenous NO donor or supplementation
with the precursor of NO (L-arginine) may prevent cardiom-
yocytic apoptosis and pathologic sequelae. This study was
designed to determine whether (1) the inhibition of endog-
enous NO production by cardioplegia or NO synthase in-
hibitor (NG-monomethyl-L-arginine, L-NMMA) aggravates
cardiomyocytic apoptosis; (2) the NO donor compound
(3-morpholinosydnonimine, SIN-1) or NO precursor used
in crystalloid cardioplegic solution attenuates postischemic
cardiomyocytic apoptosis in dogs subjected to global car-
diac arrest under CPB; and (3) NO-regulated protection was
achieved via prevention of mitochondrial complex I up-
regulation and reduction of mitochondrial damage.
Methods
Animal Model of Global Cardiac Ischemia Using
Cardiopulmonary Bypass
The experimental model was established as previously described.6
Briefly, healthy mongrel dogs (25-30 kg) of either sex were pre-
medicated with ketamine (10 mg/kg intramuscularly), anesthetized
with sodium pentobarbital (30 mg/kg intravenously), and then
given intermittent boluses of pentobarbital (5 mg/kg) and diaze-
pam (5 mg) as needed during the experiment. Each dog was
intubated and ventilated using a respirator. The left femoral artery
and vein were catheterized for hemodynamic data collection and
The Journal of Thoracifluid administration, respectively. These physiological parameters,
including heart rate, blood pressure, and maximal slope of systolic
pressure increment (dP/dT), were analyzed using a computer
equipped with an analog/digital converter (DASA 4600, Gould,
Inc, Valley View, Ohio) and software (BioCybernatics 1.0, Taipei,
Taiwan). The rectal temperature was monitored. After right tho-
racotomy, the pericardium was opened and tented to cradle the
heart. The aorta was cannulated for aortic perfusion after hepa-
rinization (250 U/kg), and the upper and lower caval veins were
transatrially cannulated for venous return. The left ventricle was
vented directly by a catheter inserted though the left atrial append-
age. Cardiopulmonary bypass was instituted with a membranous
oxygenator (Maxima Plus oxygenation system, Medtronic, Inc
Cardiopulmonary Division, Anaheim, Calif) with a flow rate at 50
mL/kg/min. After stabilization, the ascending aorta was cross-
clamped. A double-lumen aortic root cannula (DPL, Inc, Grand
Rapids, Mich) was inserted for antegrade delivery of cardioplegic
solution and simultaneous measurement of infusion pressure. All
infusions of cardioplegic solution were administered around 40 to
60 mm Hg pressure.
The body temperature during cardiopulmonary bypass was kept
around 28°C. The ascending aorta was crossclamped for 60 min-
utes, and intermittent crystalloid cold (4°C) cardioplegic solutions
(10 mL/kg) were delivered to induce cardiac arrest. The cardiople-
gic solution was reinfused (4 mL/kg) at 20-minute intervals during
global ischemia. All aspects of this investigation conformed with
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (National Institutes of
Health Publication No. 85-23, revised in 1996).
Experimental Protocol
Dogs were randomly divided into 4 groups of 6 dogs as follows:
(1) the control group received an infusion of cold crystalloid
cardioplegic solution (Plegisol, Abbott Laboratories, Chicago, Ill)
with the following electrolyte composition (in milliequivalents per
liter): calcium, 2.4; magnesium, 32; potassium, 16; sodium 120;
and chloride 160; (2) the L-arginine (L-Arg) group received an
infusion of cold crystalloid cardioplegic solution supplemented
with 2 mmol/L L-arginine; (3) the L-NMMA group was infused
with crystalloid cardioplegic solution supplemented with 400
mol/L L-NMMA; and (4) the SIN-1 group was infused with
crystalloid cardioplegic solution supplemented with 100 mol/L
SIN-1.
After 60 minutes of aortic crossclamping, the infusion of car-
dioplegic solution was stopped, the crossclamp was removed, and
systemic rewarming to 37°C was achieved. CPB was then discon-
tinued, and the mean arterial pressure was maintained at approx-
imately 50 mm Hg. After 4-hour reperfusion in the working state,
portions of the hearts were fresh harvested and stored in liquid
nitrogen until further use, while the remaining portions were
perfusion fixed with 4% paraformaldehyde before excision. Blood
samples were obtained before surgery and serially after surgery for
measurement of cardiac troponin I (cTnI) and total protein. The
blood samples were taken at baseline (before anesthetic induction),
upon establishment of CPB, after aortic crossclamp release (5
minutes), and 4 hours after reperfusion. Blood was withdrawn
from the femoral vein catheter and collected into vacuum tubes.
Platelet-poor plasma was prepared by centrifugation at 2000g for
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further use.
Plasma cTnI Analysis
Arterial blood samples (2 mL) were centrifuged at 2000g at 4°C
for 20 minutes, and the plasma was decanted for biochemical
analysis. Plasma total protein concentration was assayed using the
biuret method.8 cTnI was measured on an Axsym system (Abbott
Laboratories) and expressed as nanograms per milliliter serum. All
assays were measured without knowledge of each dog’s experi-
mental group. The detected concentrations were normalized ac-
cording to dilution factor using plasma total protein as the refer-
ence and expressed as an increase (fold) of cTnI above baseline
values.
In Vitro Apoptosis Studies
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick
end labeling (TUNEL) was performed as described previously.6
Paraffin sections were affixed to slides. After deparaffinization, the
sections were incubated in 250 L of proteinase K for 30 minutes
at 37°C and immersed in terminal deoxynucleotidyl transferase
(TdT) buffer. TdT (2.5 L), biotin-dUTP (2.5 L), and TdT buffer
(45 L) were added to cover the sections, which were incubated in
a moist chamber at 37°C for 60 minutes. The reaction was termi-
nated by transferring the slides to a buffer containing sodium
chloride (300 mmol/L) and sodium citrate (30 mmol/L) for 15
minutes at room temperature; the sections were then covered with
avidin-fluorescein isothiocyanate solution and stained with pro-
pidium iodide for 15 to 20 minutes at 4°C. After mounting, the
specimens were examined by light microscopy, and labeled nuclei
were easily identified from the unstained background. Four sec-
tions of the reperfused hearts in each animal were examined to
determine the percentage of apoptotic nuclei. To quantify apopto-
sis, 500 nuclei were identified in 10 randomly selected 400
high-power fields (HPF) per section. Apoptotic cell counts were
expressed as a percentage of the total number of nuclei counted.
The evidence of apoptosis was intensified with the Western anal-
yses of caspase-3 and poly-(ADP-ribose) polymerase (PARP) pro-
tein (the former was the final executor of apoptosis and the latter
was the substrate of caspase-3).
Reverse Transcription Polymerase Chain Reaction
For reverse transcription polymerase chain reaction (RT-PCR),
RNA was extracted from the cardiac specimens using the single-
step method9 and the concentration was determined by spectro-
photometry. RT was done using 2 L RNA in a reaction contain-
ing 50 mmol/L Tris (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl2,
1 mmol/L each of deoxynucleoside triphosphate, 0.25 g each of
oligo-deoxythymidine and random hexamer, 20 U human placental
ribonuclease inhibitor (RNasin, Promega Biochemicals, Madison,
Wis), and 400 U RT (Superscript II, Life Technologies, Rockville,
Md). The reaction was incubated at 42°C for 90 minutes and then
inactivated at 90°C for 5 minutes.
PCR reactions for NADH:ubiquinone oxidoreductase and glyc-
eraldehyde phosphate dehydrogenase (GAPDH) were done in a
25-L reaction consisting of 1 L cDNA, 10 PCR reaction
buffer (Gibco BRL, Grand Island, NY), 2.5 mmol/L each of
deoxynucleoside triphosphate, 1.125 mmol/L MgCl2, and 1
182 The Journal of Thoracic and Cardiovascular Surgery ● Augummol/L primers, and 0.625 U Taq polymerase with equal amounts
of Taq antibody and 4 Taq antibody buffer (Clontech Laborato-
ries, Inc, Palo Alto, Calif). Reactions were run at 94°C for 45
seconds, 60°C for 45 seconds, and 72°C for 1 minute 30 seconds
for 30 cycles, followed by 5 minutes at 72°C. Two NADH:
ubiquinone oxidoreductase gene-specific sense and antisense prim-
ers (29 and 22 mer, respectively) were designed to hybridize to the
detected fragment. NADH:ubiquinone oxidoreductase primers
were designed as 5'TGTTCATAATCAGGAAGGATAC-
CTAGTTC 3' (sense) and 5'GCATATTGAGCCCGGTATAGA 3'
with a 200-bp predicted product.7 DNA contamination was ex-
cluded by PCR of the same samples without previous RT. Identi-
fied signal intensities of specific PCR product bands were normal-
ized with that of the GAPDH PCR product to correct for
differences in manipulation and expressed as an increase (fold) of
mRNA expression above baseline values.
Western Blot Studies
Tissue levels of caspase-3 protein, PARP protein, Bcl-2, and
cytochrome c were determined by Western blot analyses. Because
the relative abundance of cell survival regulating factors encoded
by the Bcl-2 gene family can strongly affect the decision to
undergo apoptosis in response to an external signal,10 Western blot
analyses were performed for Bcl-2 and cytochrome c proteins.
Antiapoptotic Bcl-2 proteins have been identified in the myocar-
dium, and evidence suggests that several of these proteins are
regulated following ischemic stress.11-13 The release of Bcl-2
during ischemia-reperfusion injury from the outer membrane of
mitochondria has been proven to prevent apoptosis by blocking the
release of cytochrome c from the mitochondria.14 Ten percent
(weight/volume) tissue homogenate was prepared in the lysis
buffer and centrifuged at 4°C and 14,000g for 10 minutes. The
supernatant was separated on a 12.5% polyacrylamide denaturing
gel and then electroblotted onto Hybond-C nitrocellulose mem-
branes (Amersham Life Science, Little Chalfont, UK). Membranes
were blocked by the addition of 3% bovine serum albumin at 4°C
overnight before being probed with a polyclonal anti-caspase-3,
anti PARP antibodies (PharMingen, San Diego, Calif), a mono-
clonal anti-Bcl-2, and anti cytochrome c antibodies (PharMingen)
at 1:1000 dilution at room temperature for 2 hours. Primary anti-
body binding was revealed using an anti-rabbit peroxidase conju-
gate (Dako, Inc, Glostrup, Denmark). Positive controls for Bcl-2,
caspase-3, and PARP (NeoMarkers, Fremont, Calif) were used for
identification of the corresponding proteins. The membranes were
incubated for 1 minute with ECL detection solution, and the levels
were determined using an ECL detection kit (Amersham Pharma-
cia Biotech, Piscataway, NJ). The immunoreactive bands were
quantified by digital densitometric imaging (Kodak 1D image
analysis software, Kodak).
Data Analysis
Data are expressed as mean  standard error of the mean. Data
were entered into Excel (Microsoft Corporation, Redmond, Wash)
and analyzed by the Statistical Package for the Social Science
(SPSS Inc, Chicago, Ill) version 8.0. One-way analysis of variance
followed by Tukey multiple comparison procedure was used to
compare differences among groups.
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PResults
Reperfusion Impairment in Hemodynamic
Measurements and cTnI Levels
No significant differences in the recovery of the hemody-
namic measurements (mean blood pressure, heart rate, dP/
dT) were observed among animals in the control, L-Arg, and
SIN-1 groups at any time during the experiments (Table 1).
However, after 60 minutes of cardioplegia-induced cardiac
arrest, recovery of dP/dT in the L-NMMA group was sig-
nificantly different from that observed in the other 3 groups
(0.51  0.06 for the L-NMMA group and 0.92  0.04, 0.95
 0.09, and 0.97  0.07 for the control, L-Arg, and SIN-1
groups, respectively; P  .05), and remained significantly
different through the experimental process (Figure 1, A).
The plasma levels of cTnI at baseline and immediately upon
initiation of CPB among all 4 groups were undetectable.
However, the plasma levels of cTnI in the L-NMMA group
were significant higher than that of the other 3 groups 5
minutes after aortic crossclamps were released (85.76 6.7
ng/mL, P  .05) and 4 hours after dogs were weaned from
CPB (204.49  26.4 ng/mL, P  0.05). Nevertheless, the
plasma levels of cTnI of the control group at the above time
points (47.2  3.1 and 147.5  4.6 ng/mL, P  .05) were
also significant higher than those observed in the L-Arg
(14.0  2.1 and 24.6  6.9 ng/mL) and SIN-1 groups (21.2
 10.5 and 52.9  7.1 ng/mL; Figure 1, B).
Detection of Apoptosis in Myocardium by the TUNEL
Method
Cardiomyocyte nuclei with nicked DNA were present in all
groups. Four sections of the left ventricle in each animal
were examined to determine the percentage of apoptotic
nuclei. Apoptotic cell counts were expressed as a percentage
of the total number of nuclei counted. The percentage of
apoptotic cardiomyocyte nuclei was significantly higher in
the control (9.8  0.6%/HPF) and L-NMMA (10.3% 
1.3%/HPF) groups than in the L-Arg (5.9%  0.6%/HPF, P
 .01) and SIN-1 (3.8%  0.9%/HPF, P  .01) groups.
Furthermore, the occurrence of apoptotic cardiomyocytic
TABLE 1. Hemodynamic changes compared with baseline
clamp, off cardiopulmonary bypass, and 4 hours after repe
Group
Mean pressure
Crossclamp
off Off CPB Reperfusion
Crossclamp
off
Control 94 18 102 11 95 13 92 17
L-Arg 92 10 107 7 112 16 96 8
L-NMMA 86 11*† 84 6*† 80 7*† 98 14†
SIN-1 105 8 100 11 105 11 93 13
CPB, Cardiopulmonary bypass.
*P  .05 compared with baseline data within the same group.
†P  .05 compared with the control group at the same time point.nuclei was significantly lower in the SIN-1 group than in the
The Journal of ThoraciL-Arg group (P  .01). However, the difference in number
of apoptotic nuclei between the control and L-NMMA
groups was not statistically significant (Figure 2, B).
Detection of Caspase-3 Activation by Western Blotting
Caspase-3 plays a role as a key protease of the apoptotic
machinery. We examined whether global cardiac ischemia/
reperfusion actually induced caspase-3 cleavage as a pre-
requisite for caspase-3 enzymatic activity. As PARP protein
is known to be a major substrate for active caspase-3 and
PARP degradation (a hallmark of apoptosis), Western blot
analysis for PARP protein was performed. The intact 116-
kDa PARP was degraded, as shown by the increasing quan-
tity of 24-kDa cleavage product detected using N-terminal
binding antibody (Figure 2, C). Using densitometry analy-
ses, we found that levels of activated caspase-3 levels were
higher in the control (4312  498) and L-NMMA (6053 
253) groups than in the L-Arg (3646  399, P  .05 and P
 .01, respectively) and SIN-1 (1731  437, P  .01 and
P  0.01, respectively; Figure 2, A) groups.
Detection of NADH:Ubiquinone Oxidoreductase Gene
Up-regulation by RT-PCR
RT-PCR of mRNA from the cardiac tissue specimens con-
firmed the presence and differential up-regulation of the
NADH:ubiquinone oxidoreductase gene among the 4
groups. As shown in Figure 3, RT-PCR detected NADH:
ubiquinone oxidoreductase gene protein mRNA up-regula-
tion in cardiac tissue in all 4 groups. Densitometric semi-
quantitative analysis implied significant up-regulation in the
control (6698  256, P  .01) and L-NMMA (9268  176,
P  .01) groups compared with the SIN-1 group (2357 
141). The mRNA up-regulation observed in the L-Arg group
(4198  312) was also significantly lower than that of the
control (P  .01) and L-NMMA (P  .01) groups. How-
ever, the difference in mRNA up-regulation between the
SIN-1 and L-Arg (P  .01) groups and the L-NMMA and
control (P  .01) groups was also statistically significant.
In our study, Bcl-2 and cytochrome c protein expression
of various groups immediately after release of the aortic
ion
eart rate dP/dT
Off CPB Reperfusion
Crossclamp
off Off CPB Reperfusion
 12 94 17 92 4 92 3 96 1
 18 114 23 95 19 87 19 107 9
 11*† 84 12*† 51 6*† 57 12*† 76 6*†
 9 95 12 97 7 94 12 94 8(%)
rfus
H
94
91
81
96was significantly different in the L-Arg and SIN-1 groups
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compared with the control and L-NMMA groups (P  .05,
Figure 4, A). Densitometry analyses showed that the levels
(expressed in optical density units) of Bcl-2 were signifi-
cantly higher in the SIN-1 (3060 247) and L-Arg (3145
158) groups than in the control (1490  163, P  .05 for
both comparisons) and L-NMMA (490  79, P  .05 for
both comparisons) groups. On the other hand, the SIN-1
(10772  2046, P  .05 for both comparisons) and L-Arg
(12155  1938, P  .05 for both comparisons) groups
significantly decreased the expression of cytochrome c than
the control (15074  1059) and L-NMMA (16982  1588;
Figure 4, B) groups. However, the expression of both pro-
teins was not significantly different between the SIN-1 and
Figure 1. Relationship among various groups, relea
reperfusion. A, Recovery of dP/dT 5 minutes after relea
dogs were weaned off CPB (off CPB), and 4 hours afte
levels of cTnI collected at different time points in all
using CPB. Data are presented as the mean  standard
versus both control and L-NMMA groups.L-Arg groups and the control and L-NMMA groups.
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In the development of cardioplegic cardioprotection during
cardiac surgery, many different formulations of cardiople-
gic solutions have been investigated and applied in clinical
use. Using various methods of cardioprotection, cardiom-
yocytic necrosis can be minimized in modern cardiac sur-
gery. However, cardiomyocytic apoptosis occurs when isch-
emic insult is delivered in doses milder than that required
for necrosis.15 Despite improvements made in every
method, ischemia-reperfusion injury of cardiomyocytes oc-
curs during aortic crossclamping, even with continuous
tepid blood cardioplegic solution cardioprotection. Apopto-
sis may be involved in the progression of dilated cardiomy-
f cardiac troponin I, and recovery of dP/dT during
the aortic crossclamp (off crossclamp), 5 minutes after
B termination (reperfusion) in the 4 groups. B, Plasma
oups undergoing global cardiac ischemia-reperfusion
r of the mean. *P < .05 versus control group. #P < .05se o
sing
r CP
4 gr
erroopathy, in that loss of cardiomyocytes promotes myocardial
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Pdysfunction, resulting in heart failure. Furthermore, apopto-
sis was proven to be evident early after cardiac surgery and
5
Figure 2. Effect of NO-enriched cardioplegia on cardiop
B, The number of apoptotic nuclei in different gro
transferase-mediated dUTP-biotin nick end labeling)
poly-(ADP-ribose) polymerase (PARP) in different gr
activated caspase-3 of the control and L-NMMA group
*P < .05 versus control and < .01 versus L-NMMA gr
Figure 3. Reverse-transcription polymerase chain re
ubiquinone oxidoreductase gene in cardiac tissue in t
genase (GAPDH) served as the loading control. The PCR
gene were designed to be 200 bp. *P < .01 versus cocorrelates with declining cardiac contractility.
The Journal of ThoraciOur previous studies revealed that different cardioplegic
solutions have various effects on the occurrence of coronary
6
nary bypass (CPB)–induced cardiomyocytic apoptosis.
stained with the TUNEL (terminal deoxynucleotidyl
hod. C, Western blot analysis of caspase-3 (A) and
was performed. Using densitometry analyses, the
re significantly higher than that of the other 2 groups.
n analysis showing up-regulation of part of NADH:
ifferent groups. Glyceraldehyde-3-phosphate dehydro-
ducts of GAPDH and NADH:ubiquinone oxidoreductase
.ulmo
ups
met
oups
s we
oup.actio
he d
proendothelial damage and cardiomyocytic apoptosis and sug-
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none oxidoreductase in this process.7 The anatomic impair-
ment of coronary endothelium during cardioplegic cardiac
arrest is associated with the deterioration its vasorelaxation
function,16,17 which is mediated largely via NO. NO can
protect cells from apoptosis induced by many different
types of stimuli such as tumor necrosis factor-, oxidative
stress, and serum or glucose deprivation.18 The biochemical
mechanism underlying NO-mediated antiapoptotic effects
involves multiple signal pathways, including the mitochon-
dria-dependent pathway. NO can rapidly inactivate mito-
chondrial complex I,19 elevate mRNA and protein levels of
Bcl-2 expression, and prevent apoptotic cell death.20 How-
ever, these effects could be abolished with cardioplegia-
induced cardiac ischemia-reperfusion injury under CPB,
which had similar results as inhibition of NO synthase.19
Mitochondrial complex I, which produces superoxide, has
been reported to be associated with an increased hydrogen
peroxide production21 and cardiomyocytic damage22 after
7
Figure 4. Western blot analysis of Bcl-2 and cytochrom
and L-NMMA groups), (B) cytochrome c (*P < .05 versischemia-reperfusion injury. In our previous study, we
186 The Journal of Thoracic and Cardiovascular Surgery ● Augudemonstrated that with better cardiomyocytic preservation,
the up-regulation of part of the mitochondrial complex I and
cardiomyocytic apoptosis was lessened. Thus, we hypothe-
sized that NO-enriched cardioplegic solution could decrease
the occurrence of cardiomyocytic apoptosis by activation of
Bcl-2 protein, prevent the up-regulation of mitochondrial
NADH:ubiquinone oxidoreductase, diminish the release of
cytochrome c from mitochondria, and ameliorate the acti-
vation of caspase cascade.
The impact of ischemia-reperfusion insult on the car-
diomyocytic mitochondrial respiratory chain has been stud-
ied previously. Kotamraju and colleagues22 suggested that
mitochondrial electron transfer complex I might represent
the primary site of hydrogen peroxide formation and suc-
ceeding cardiomyocytic apoptosis. Hardy and coworkers23
reported that the activity of complex I decreased following
reperfusion, which resulted in an increase in intracellular
Ca2. They also demonstrated that following a hypoxic
episode, the increased activity of mitochondrial complex I
7
in different groups: (A) Bcl-2 (*P < .05 versus control
ontrol and L-NMMA groups).e c
us cwould impair myocardial recovery. In our previous study,
st 2004
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Pwe indicated that during global cardiac arrest under CPB,
cardiomyocytic mitochondrial up-regulation correlated with
the occurrence of cardiomyocytic apoptosis, which implied
that with better myocardial protection, ischemia-reperfu-
sion–induced mitochondrial complex I mRNA up-regula-
tion would be reduced. In this study, we used an NO-
enriched cardioplegic solution to supplement the
deteriorated endothelial NO production. Our results suggest
that prevention of the mitochondrial complex I up-regula-
tion might be 1 possible mechanism of how NO-enriched
cardioplegic solution ameliorated ischemia-reperfusion in-
jury to the cardiomyocytes.
The activation of caspases by proapoptotic stimuli occurs
via several interdependent pathways. Whether a cell under-
goes apoptosis appears to be due to a shift in the balance
between anti- and proapoptotic factors in favor of the “pro”
factors. Kim and colleagues24 reported that physiologically
relevant levels of NO can contribute to this balance by
modulating the level of caspase-3–like protease activity
through both direct and indirect mechanisms. Exogenous
NO-donating agents clearly can elicit beneficial actions
relevant to cardiovascular disorders.25 NO has been postu-
lated to inhibit apoptosis by a variety of mechanisms in-
cluding inhibition of transcription factor–dependent Fas
ligand expression,26 cyclic guanosine monophosphate–
dependent signaling cascades,27 and direct nitrosylation of
caspases-3 and -8.24 An important type of apoptosis, which
is mediated via mitochondria, is the direct cytochrome
c–dependent activation of caspase-3.28 NO could also main-
tain the mitochondrial membrane potential during stimuli,
regulate the Bcl-2 proteins, decrease cytochrome c release,
and prevent cell apoptosis.29 Matsumoto and colleagues30
demonstrated the interaction between NO synthase and pro-
caspase-3 could be modified with L-arginine or L-NMMA
via the mitochondrial pathway.30 Damage to the vascular
endothelium during global cardiac arrest using cardioplegic
solution under CPB has been documented,17 and the im-
pairment of endothelium results in decreasing production of
NO. With a disturbance in the NO production balance, the
NO-mediated antiapoptotic pathway would be inhibited. In
this study, we demonstrated that restoration of the physio-
logic NO production balance could resume the NO-medi-
ated antiapoptotic pathway, increasing the expression of
Bcl-2 proteins and ameliorating cytochrome c release, thus
protecting the cardiomyocytes from apoptosis. On the other
hand, inhibition of NO synthase would diminish the pro-
duction of NO and aggravate apoptosis after cardioplegia-
induced cardiac global ischemia-reperfusion injury under
CPB.
In the present study, we demonstrated that: (1) cardiople-
gic solutions supplemented with NO donor (SIN-1) or NO
synthase substrate (L-arginine) could elevate the expression
of Bcl-2, which inhibits the mitochondrial pathway of apo-
The Journal of Thoraciptosis; (2) cardioplegic solutions supplemented with NO
donor (SIN-1) or NO synthase substrate (L-arginine) could
decrease the up-regulation of mitochondrial NADH:ubiqui-
none oxidoreductase mRNA; (3) cardioplegic solutions sup-
plemented with NO donor (SIN-1) or NO synthase substrate
(L-arginine) could inhibit apoptosis downstream of cyto-
chrome c release; (4) cardioplegic solutions supplemented
with NO donor (SIN-1) or NO synthase substrate (L-argi-
nine) could inhibit caspase 3 activation in cells; and (5)
cardioplegic solutions supplemented with NO synthase in-
hibitor (L-NMMA) could increase the up-regulation of mi-
tochondrial NADH:ubiquinone oxidoreductase mRNA, de-
crease the expression of Bcl-2, elevate the expression of
caspase-3, and aggravate cardiomyocytic apoptosis. These
data indicate that NO-enriched cardioplegic solutions may
inhibit the mitochondrial pathway of apoptosis by preven-
tion of the NADH:ubiquinone oxidoreductase up-regula-
tion. These findings have implications for the mechanisms
of cardiomyocytic apoptosis that arise during global cardiac
arrest due to the use of cardioplegic solution during CPB
and also suggest prevention strategies for postoperative
myocardial failure.
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